In patients with heart failure with reduced or preserved ejection fraction, when is finerenone preferred over spironolactone based on estimated glomerular filtration rate (eGFR), serum potassium level, and risk of hormonal adverse effects?

Finerenone vs Spironolactone in Heart Failure

Finerenone is preferred over spironolactone in heart failure patients with lower eGFR (25-30 mL/min/1.73 m²), those at higher risk for hyperkalemia, and men experiencing gynecomastia or sexual dysfunction from steroidal MRAs.

Key Decision Points

eGFR Thresholds

Finerenone has a clear advantage in moderate-to-severe CKD:

• Finerenone can be initiated down to eGFR ≥25 mL/min/1.73 m² 1
• Spironolactone should not be initiated below eGFR 30 mL/min/1.73 m² 2, 3

This 5 mL/min/1.73 m² window (25-30) represents a critical zone where finerenone is the only MRA option. For patients with eGFR 30-50 mL/min/1.73 m², both agents can be used, but finerenone may offer superior safety given its lower hyperkalemia discontinuation rates 4.

Potassium Management

Initiation thresholds differ slightly:

• Finerenone: Potassium must be ≤4.8 mmol/L (trial criteria) or ≤5.0 mmol/L (FDA label) 1
• Spironolactone: Potassium must be <5.0 mEq/L 2, 5

During treatment, finerenone demonstrates better hyperkalemia profiles:

• In FIGARO-DKD/FIDELIO-DKD pooled analysis, only 1.2% discontinued finerenone due to hyperkalemia despite 10.8% experiencing elevated potassium 4
• Real-world data suggests finerenone has lower hyperkalemia risk than spironolactone in HFrEF (RR 0.41,95% CI 0.21-0.79) 6
• Finerenone showed lower severe hyperkalemia rates (HR 0.57,95% CI 0.40-0.83) in cardio-oncology patients 7

Management algorithm when potassium rises:

• >5.5 mmol/L: Withhold finerenone; restart at 10 mg when ≤5.0 mmol/L 1
• >5.5 mmol/L: Halve spironolactone dose (e.g., 25 mg every other day) 8, 2
• >6.0 mmol/L: Stop either agent immediately 8, 2

Heart Failure Phenotype Considerations

For HFrEF (LVEF ≤40%):

• Spironolactone has decades of Class I evidence (RALES trial: 30% mortality reduction) 8, 2, 5
• Finerenone lacks dedicated HFrEF outcome trials but shows promise in real-world data 7, 6
• Choose spironolactone first unless contraindicated by renal function, potassium, or hormonal side effects

For HFmrEF/HFpEF (LVEF ≥40%):

• Finerenone is now the evidence-based choice based on FINEARTS-HF (6,001 patients, 14% reduction in CV death/HF events) 3, 9, 10
• Spironolactone showed inconsistent benefits in TOPCAT, with geographic heterogeneity 3
• The 2025 Canadian guidelines give finerenone a strong recommendation for HFpEF/HFmrEF 3

For diabetic kidney disease with HF:

• Finerenone is strongly preferred given proven cardiovascular and renal benefits in FIDELITY analysis (14% CV event reduction, 23% kidney outcome reduction) 1, 4, 1
• This applies to patients with T2DM, eGFR ≥25 mL/min/1.73 m², and albuminuria (ACR ≥30 mg/g) 1

Hormonal Adverse Effects

Finerenone's nonsteroidal structure eliminates sex hormone receptor binding:

• Spironolactone causes gynecomastia in 10% of men (vs placebo in RALES) 8
• Spironolactone also causes impotence and breast discomfort 8, 3
• Finerenone has no off-target androgen/progesterone receptor effects 3, 9
• Switch to finerenone in men experiencing these symptoms 8, 3

Practical Dosing Algorithms

Finerenone Initiation

• eGFR >60 mL/min/1.73 m²: Start 20 mg daily
• eGFR 25-60 mL/min/1.73 m²: Start 10 mg daily
• Uptitrate to 20 mg after 4 weeks if potassium ≤4.8 mmol/L and eGFR stable 1, 11
• Monitor potassium/creatinine at 4 weeks after any dose change 1, 3

Spironolactone Initiation

• eGFR ≥50 mL/min/1.73 m²: Start 25 mg daily
• eGFR 30-49 mL/min/1.73 m²: Start 25 mg every other day or 12.5 mg daily 2, 5
• Uptitrate to 50 mg daily after 4-8 weeks if tolerated 8, 2
• Monitor potassium/creatinine at 2-3 days, 7 days, then monthly × 3 months 2

Critical Contraindications

Absolute contraindications for both agents:

• Potassium >5.0 mEq/L at baseline 2, 3
• Concurrent ACEi + ARB combination 8

Spironolactone-specific:

• eGFR <30 mL/min/1.73 m² 2, 3
• Creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) 2

Finerenone-specific:

• eGFR <25 mL/min/1.73 m² 1, 3, 1

Common Pitfalls

1. Failing to dose-reduce in moderate CKD: Spironolactone at eGFR 30-49 requires every-other-day dosing initially 2
2. Inadequate monitoring: Both agents require potassium checks within 1 week of initiation or dose changes 2, 3
3. Continuing NSAIDs: These dramatically increase hyperkalemia risk—counsel patients to avoid 2
4. Stopping potassium supplements: Discontinue or reduce these when starting MRAs 2
5. Using spironolactone in advanced CKD: Below eGFR 30, only finerenone is appropriate 1, 3, 1

Cost and Accessibility Considerations

The 2025 Canadian guidelines acknowledge that steroidal MRAs are widely accessible and generally affordable 3, while finerenone represents a newer, likely more expensive option. However, the evidence boundaries are clear: when eGFR is 25-30 mL/min/1.73 m², when LVEF ≥40%, or when hormonal side effects occur, finerenone is not just preferred but often the only appropriate choice 1, 3, 1.